Targeted protein degradation is a new therapeutic modality based on drugs that destabilize
proteins by inducing their proximity to E3 ubiquitin ligases. Of particular interest are …

Targeted protein degradation (TPD) is a rapidly developing field in chemical biology and
drug discovery. Various TPD modalities have emerged, with proteolysis-targeting chimeras …

Diverging from traditional target inhibition, proteasomal protein degradation approaches
have emerged as novel therapeutic modalities that embody distinct pharmacological profiles …

Targeted protein degradation (TPD), the ability to control a proteins fate by triggering its
degradation in a highly selective and effective manner, has created tremendous excitement …

Redirecting E3 ligases to neo-substrates, leading to their proteasomal disassembly, known
as targeted protein degradation (TPD), has emerged as a promising alternative to traditional …

Molecular-glue-mediated proximity-induced degradation now allows unprecedented
therapeutic targeting of previously undruggable proteins. Structures showing how aryl …

In recent years, with the successful development of proteolysis-targeting chimeric molecules
(PROTACs), the potential of heterobifunctional molecules to contribute to reenvisioning drug …

Proteolysis targeting chimeras (PROTACs) are bispecific molecules containing a target
protein binder and an ubiquitin ligase binder connected by a linker. By recruiting an …

Small-molecule drug discovery has traditionally focused on occupancy of a binding site that
directly affects protein function, and this approach typically precludes targeting proteins that …

Traditional drug discovery mainly focuses on direct regulation of protein activity. The
development and application of protein activity modulators, particularly inhibitors, has been …